Supplementary Eye Fields

The supplementary eye fields (SEFs) are located in dorsomedial frontal cortex and contribute to high-level control of eye movements. Recordings in the SEF reveal neural activity related to vision, saccades, and fixations, and electrical stimulation in the SEF evokes saccades and fixations. Inactivations and lesions of the SEF, however, cause minimal oculomotor deficits. The SEF thus processes information relevant to eye movements and influences critical oculomotor centers but seems unnecessary for generating action. Instead, the SEF has overarching, subtle functions that include limb-eye coordination, the timing and sequencing of actions, learning, monitoring conflict, prediction, supervising behavior, value-based decision making, and the monitoring of decisions.

Supplementary Eye Fields

The supplementary eye fields (SEFs) are located in dorsomedial frontal cortex and contribute to high-level control of eye movements. Recordings in the SEF reveal neural activity related to vision, saccades, and fixations, and electrical stimulation in the SEF evokes saccades and fixations. Inactivations and lesions of the SEF, however, cause minimal oculomotor deficits. The SEF thus processes information relevant to eye movements and influences critical oculomotor centers but seems unnecessary for generating action. Instead, the SEF has overarching, subtle functions that include limb-eye coordination, the timing and sequencing of actions, learning, monitoring conflict, prediction, supervising behavior, value-based decision making, and the monitoring of decisions.

Competing Actions of Type 1 Angiotensin II Receptors Expressed on T Lymphocytes and Kidney Epithelium during Cisplatin-Induced AKI.

Inappropriate activation of the renin-angiotensin system (RAS) contributes to many CKDs. However, the role of the RAS in modulating AKI requires elucidation, particularly because stimulating type 1 angiotensin II (AT1) receptors in the kidney or circulating inflammatory cells can have opposing effects on the generation of inflammatory mediators that underpin the pathogenesis of AKI. For example, TNF-α is a fundamental driver of cisplatin nephrotoxicity, and generation of TNF-α is suppressed or enhanced by AT1 receptor signaling in T lymphocytes or the distal nephron, respectively. In this study, cell tracking experiments with CD4-Cre mT/mG reporter mice revealed robust infiltration of T lymphocytes into the kidney after cisplatin injection. Notably, knockout of AT1 receptors on T lymphocytes exacerbated the severity of cisplatin-induced AKI and enhanced the cisplatin-induced increase in TNF-α levels locally within the kidney and in the systemic circulation. In contrast, knockout of AT1 receptors on kidney epithelial cells ameliorated the severity of AKI and suppressed local and systemic TNF-α production induced by cisplatin. Finally, disrupting TNF-α production specifically within the renal tubular epithelium attenuated the AKI and the increase in circulating TNF-α levels induced by cisplatin. These results illustrate discrepant tissue-specific effects of RAS stimulation on cisplatin nephrotoxicity and raise the concern that inflammatory mediators produced by renal parenchymal cells may influence the function of remote organs by altering systemic cytokine levels. Our findings suggest selective inhibition of AT1 receptors within the nephron as a promising intervention for protecting patients from cisplatin-induced nephrotoxicity.